{"ticker": {"uuid": "650eec91-b4a7-428c-af90-dc62440df81b", "symbol": "SCTX", "name": "Scribe Therapeutics Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "charts": {"tiers": [{"count": 25, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 17, "label": "Market update"}, {"count": 5, "label": "Earnings"}, {"count": 3, "label": "Deals and strategy"}], "sources": [{"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 4}, {"label": "Zacks Investment Research", "count": 3}, {"label": "Fierce Biotech", "count": 2}, {"label": "Benzinga", "count": 1}, {"label": "Market source", "count": 1}, {"label": "WSJ", "count": 1}, {"label": "Latham & Watkins LLP", "count": 1}]}, "insights": [{"text": "Early balanced news score", "tone": "neutral", "label": "Weighted tone", "value": "50/100"}, {"text": "1.0 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "17/100"}, {"text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "tone": "neutral", "label": "Market reaction", "value": "Early company-news score"}, {"text": "84/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Market update"}, {"text": "100% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "25"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "positive", "label": "Evidence agreement", "value": "0/100"}, {"text": "-20.3% over one week, - over four weeks, trend inactive, and near fair-value range.", "tone": "negative", "label": "Trend context", "value": "Trend inactive"}, {"text": "Scribe Therapeutics (SCTX) Stock Analysis Report | Financials & Insights", "tone": "neutral", "label": "Latest direct headline", "value": "Neutral"}], "classifier": {"events": [{"count": 17, "event": "general", "label": "Market update", "weight": 10.78}, {"count": 5, "event": "earnings", "label": "Earnings", "weight": 3.2}, {"count": 3, "event": "deals", "label": "Deals and strategy", "weight": 1.8}], "pipeline": {"eodhd": {"status": "healthy", "calls_used": 32790, "configured": true, "last_error": "", "rate_limit": 1200, "call_budget": 90000, "requests_made": 6558, "newest_seen_at": "2026-08-17T03:57:00+00:00", "rate_remaining": 1191, "budget_used_pct": 36.4, "last_success_at": "2026-08-17T04:21:49.488115+00:00", "mapped_mentions": 3654, "unmapped_mentions": 2738}, "status": "healthy", "raw_articles": 52, "eodhd_articles": 8, "unique_stories": 32, "direct_evidence": 25, "provider_counts": {"eodhd": 9, "google_news": 13, "alphavantage": 12}, "provider_errors": {}, "archive_articles": 3, "current_evidence": 1, "provider_seconds": {"eodhd": 0.125, "google_news": 0.368, "alphavantage": 0.429}, "relevant_stories": 25, "duplicates_removed": 20, "durable_story_count": 18, "providers_attempted": 3, "durable_collected_at": "2026-08-15T22:14:57.240585+00:00", "durable_evidence_used": true, "providers_with_results": 3, "matched_archive_stories": 25, "provider_rejected_counts": {"eodhd": 7, "google_news": 2, "alphavantage": 0}, "provider_relevant_counts": {"eodhd": 2, "google_news": 11, "alphavantage": 12}, "durable_newest_article_at": "2026-08-15T05:51:35+00:00"}, "confidence": 84, "primary_event": "general", "primary_label": "Market update", "negative_events": 0, "positive_events": 1}, "updated_at": "2026-08-17T04:24:40.163174+00:00", "total_unique": 25, "total_fetched": 25, "interpretation": {"tone": "neutral", "label": "Early company-news score", "risks": [], "badges": ["Provisional evidence"], "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 17, "event_label": "Market update", "opportunities": [], "classification": "provisional", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "negative", "latest_week": "2026-08-14", "trend_label": "Trend inactive", "latest_close": 20.73, "trend_signal": "0", "one_week_move": -20.3, "reaction_tone": "negative", "fair_value_gap": -5.6, "four_week_move": null, "reaction_label": "Price reacting lower", "fair_value_tone": "neutral", "market_dynamics": 0.0, "market_sentence": "-20.3% over one week, - over four weeks, trend inactive, and near fair-value range.", "fair_value_label": "Near fair-value range", "twelve_week_move": null, "relative_strength": null, "has_market_context": true, "expectation_direction": "positive", "expectation_probability": 58.4906, "market_dynamics_buy_signal": false}, "total_relevant": 25, "pipeline_health": {"eodhd": {"status": "healthy", "calls_used": 32790, "configured": true, "last_error": "", "rate_limit": 1200, "call_budget": 90000, "requests_made": 6558, "newest_seen_at": "2026-08-17T03:57:00+00:00", "rate_remaining": 1191, "budget_used_pct": 36.4, "last_success_at": "2026-08-17T04:21:49.488115+00:00", "mapped_mentions": 3654, "unmapped_mentions": 2738}, "status": "healthy", "raw_articles": 52, "eodhd_articles": 8, "unique_stories": 32, "direct_evidence": 25, "provider_counts": {"eodhd": 9, "google_news": 13, "alphavantage": 12}, "provider_errors": {}, "archive_articles": 3, "current_evidence": 1, "provider_seconds": {"eodhd": 0.125, "google_news": 0.368, "alphavantage": 0.429}, "relevant_stories": 25, "duplicates_removed": 20, "durable_story_count": 25, "providers_attempted": 3, "durable_collected_at": "2026-08-17T04:24:40.163174+00:00", "durable_evidence_used": true, "providers_with_results": 3, "matched_archive_stories": 25, "provider_rejected_counts": {"eodhd": 7, "google_news": 2, "alphavantage": 0}, "provider_relevant_counts": {"eodhd": 2, "google_news": 11, "alphavantage": 12}, "durable_newest_article_at": "2026-08-17T00:44:57+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Early balanced news score", "score": 50, "total": 25, "neutral": 24, "negative": 0, "positive": 1, "raw_score": 62, "confidence": 17, "dispersion": 0, "story_count": 25, "window_days": 30, "direct_share": 100, "source_count": 1, "score_version": "evidence-v10", "evidence_count": 1, "evidence_status": "provisional", "information_mass": 0.0, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-17T00:44:57+00:00", "direct_story_count": 25, "effective_articles": 1.0, "sector_story_count": 0, "direct_source_count": 1, "industry_story_count": 0, "source_concentration": 1.0, "directional_story_count": 1}, "articles": [{"url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE5pR3NWa2dyendscW05RG1SRFhTdnI5V1g5MDg4X19KS25xTTJiUWJiSEFPRks3X0JTc2otVVZrUjlfd1pOeEtlem5WdFdpOFdTbkJjNA?oc=5", "tier": "direct", "title": "Scribe Therapeutics (SCTX) Stock Analysis Report | Financials & Insights", "topics": [], "summary": "", "age_days": 0.2, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE5pR3NWa2dyendscW05RG1SRFhTdnI5V1g5MDg4X19KS25xTTJiUWJiSEFPRks3X0JTc2otVVZrUjlfd1pOeEtlem5WdFdpOFdTbkJjNA?oc=5", "source_name": "Benzinga", "published_at": "2026-08-17T00:44:57+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 94.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.06905, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "17 Aug 2026 00:44", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE8yRXBrQjdLRzk0Wk9OQzVYOXdyMXhvejdUekZfTG85NXRoQjcwQlExYm1JMG9XNEZxS011Xy1tWEpEVGFvVXVkVDc0cVNtU0Yya0ZCZS1QNGZOVWI4S3ZwRnl6dUJUZG5sYUYxQw?oc=5", "tier": "direct", "title": "Should I buy Scribe Therapeutics Inc. (SCTX)", "topics": [], "summary": "", "age_days": 1.0, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMibEFVX3lxTE8yRXBrQjdLRzk0Wk9OQzVYOXdyMXhvejdUekZfTG85NXRoQjcwQlExYm1JMG9XNEZxS011Xy1tWEpEVGFvVXVkVDc0cVNtU0Yya0ZCZS1QNGZOVWI4S3ZwRnl6dUJUZG5sYUYxQw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-08-16T04:38:46+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 71.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.044266, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "16 Aug 2026 04:38", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9HWXFrSHg3NGx0dWloNEVrUGJUUHFYSGc4THZ0cldjaWdMM01IbGhEWW1UMHVNNmdWay1vNWw4QVVzY19fUFEzWnpiQ0tOVk1xSjZ2VzNvcUdSUEhxdlFWR1hrSmFBOVFFUWc?oc=5", "tier": "direct", "title": "What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement", "topics": [], "summary": "", "age_days": 1.3, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9HWXFrSHg3NGx0dWloNEVrUGJUUHFYSGc4THZ0cldjaWdMM01IbGhEWW1UMHVNNmdWay1vNWw4QVVzY19fUFEzWnpiQ0tOVk1xSjZ2VzNvcUdSUEhxdlFWR1hrSmFBOVFFUWc?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-08-15T20:02:04+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 82.9, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.092896, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "15 Aug 2026 20:02", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-fecef9420a3a.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX) awards 14,725 stock options to director Bleharski", "topics": ["Finance", "Life Sciences"], "summary": "Scribe Therapeutics (SCTX) director Joshua Bleharski was granted 14,725 stock options with an exercise price of $15.00 per share, expiring on July 22, 2036. The options will vest in three equal annual installments on July 23 of 2027, 2028, and 2029, contingent on his continued service to the company. This transaction is classified as a compensation award, not a market purchase.", "age_days": 3.7, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-fecef9420a3a.html", "source_name": "Stock Titan", "published_at": "2026-08-13T12:41:35", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 28.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.017582, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 12:41", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/schedule-13d-scribe-therapeutics-inc-major-shareholder-acquisition-5-de46eae4702d.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX): Avoro group reports 16.37% ownership after IPO", "topics": ["Finance", "IPO", "Life Sciences"], "summary": "Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have reported a collective beneficial ownership of 16.37% in Scribe Therapeutics, Inc. (SCTX) common stock following the company's IPO. This stake, totaling 3,088,888 shares, arose from the conversion of Series B preferred stock, purchases during the IPO, and open-market transactions. The entities are subject to customary lock-up agreements and registration rights.", "age_days": 4.9, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/schedule-13d-scribe-therapeutics-inc-major-shareholder-acquisition-5-de46eae4702d.html", "source_name": "Stock Titan", "published_at": "2026-08-12T05:41:00", "tone_signals": ["Business expansion"], "company_focus": 1.0, "freshness_pct": 61.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.069747, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 05:41", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-d5d81f63441d.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX) CFO gets major option grants and family share buys", "topics": ["Finance", "IPO", "Life Sciences"], "summary": "Scribe Therapeutics CFO David Parrot received significant equity awards, including time-vested and performance-based stock options totaling over 200,000 shares, both priced at $15.00. He also reported indirect open-market purchases of 2,666 common shares for family members at the same price. These transactions follow a prior option grant disclosed in connection with the company's initial public offering.", "age_days": 5.4, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-d5d81f63441d.html", "source_name": "Stock Titan", "published_at": "2026-08-11T19:40:24", "tone_signals": ["Business expansion"], "company_focus": 1.0, "freshness_pct": 15.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.01281, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Aug 2026 19:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-1e8d36b8c544.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX) CEO receives time- and performance-based option grants", "topics": ["Finance", "IPO", "Life Sciences"], "summary": "Scribe Therapeutics CEO Benjamin L. Oakes received three option awards for the company's common stock. These include a fully vested grant of 12,969 options on March 13, 2026, and two grants on July 23, 2026: a time-based option for 264,784 shares vesting monthly over four years, and a performance-based option for 429,599 shares contingent on market-based performance criteria. The filing also provides details on vesting schedules, exercise prices, and expiration dates for these grants.", "age_days": 5.4, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-1e8d36b8c544.html", "source_name": "Stock Titan", "published_at": "2026-08-11T19:40:24", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 15.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.009723, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Aug 2026 19:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQaHJRblljWVRnakc4ZW9qa1ZabS1NOHU5SDBCYzVnRVFxV3VrRnNMSUVGX1JOTmhPNTRpbTUwN1VCSkRTS3lzdDhycXkzcHBFWVR3a05lRDByWFEzWGhaVnB3ME1CVnFTQ0pXMDdjbHVJdTdWYmVGR2JTY1N6R0M2d2ItWWptMnJXYzBXVmJHOVkza2ZiRVhpX194bFJ5NjRrZVE4aWpSb1dZRzBrb1RGMllYX2Fqa0tn?oc=5", "tier": "direct", "title": "Scribe Therapeutics (SCTX) grants 14,725 options to Aghazadeh and Avoro entities", "topics": [], "summary": "", "age_days": 6.4, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQaHJRblljWVRnakc4ZW9qa1ZabS1NOHU5SDBCYzVnRVFxV3VrRnNMSUVGX1JOTmhPNTRpbTUwN1VCSkRTS3lzdDhycXkzcHBFWVR3a05lRDByWFEzWGhaVnB3ME1CVnFTQ0pXMDdjbHVJdTdWYmVGR2JTY1N6R0M2d2ItWWptMnJXYzBXVmJHOVkza2ZiRVhpX194bFJ5NjRrZVE4aWpSb1dZRzBrb1RGMllYX2Fqa0tn?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-10T20:00:12+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 11.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.00592, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 20:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/form-3-scribe-therapeutics-inc-initial-statement-of-beneficial-owners-418b6a014f13.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX) ten percent owner Brett Staahl reports stock and option holdings", "topics": ["Finance", "Life Sciences"], "summary": "Scribe Therapeutics (SCTX) ten percent owner Brett Staahl has filed an initial statement of beneficial ownership, reporting 524,336 shares of Common Stock held directly. Additionally, Staahl holds four stock option awards with various exercise prices and expiration dates ranging from 2030 to 2036, covering a total of 26,703 underlying shares. Some of these options are fully vested, while others have a vesting schedule that began on January 1, 2026.", "age_days": 6.4, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/form-3-scribe-therapeutics-inc-initial-statement-of-beneficial-owners-418b6a014f13.html", "source_name": "Stock Titan", "published_at": "2026-08-10T17:40:28", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 10.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.00668, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 17:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.tradingview.com/symbols/NASDAQ-SCTX/financials-cash-flow/free-cash-flow", "tier": "direct", "title": "Free cash flow of Scribe Therapeutics Inc. \u2013 NASDAQ:SCTX", "topics": ["Earnings", "Life Sciences"], "summary": "This article provides a brief mention of the free cash flow for Scribe Therapeutics Inc. (NASDAQ: SCTX) as found on TradingView. It appears to be a financial data point without further analysis or details within the snippet provided. The primary content available is navigational and structural information related to the TradingView platform.", "age_days": 11.2, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/symbols/NASDAQ-SCTX/financials-cash-flow/free-cash-flow", "source_name": "TradingView", "published_at": "2026-08-05T23:11:13", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 21.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.020272, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "05 Aug 2026 23:11", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9iVDF6WFNnRnZPVU95cjRPcTFDSGt5UGhoS0w1UjNjSmN2QmlBTnpNd2trUmgwZFFqZG4wdlNUR282X1pJM3FhT2R5bVZWVm01eTR1VU5KeEVObmxod3dOVVpvMzZJRERTaE5iYnUxUQ?oc=5", "tier": "direct", "title": "Scribe Therapeutics Inc. (SCTX) Revenue (TTM)", "topics": [], "summary": "", "age_days": 13.8, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9iVDF6WFNnRnZPVU95cjRPcTFDSGt5UGhoS0w1UjNjSmN2QmlBTnpNd2trUmgwZFFqZG4wdlNUR282X1pJM3FhT2R5bVZWVm01eTR1VU5KeEVObmxod3dOVVpvMzZJRERTaE5iYnUxUQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-08-03T08:37:25+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 14.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.014122, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "03 Aug 2026 08:37", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.tradingview.com/news/tradingview:5a18ca4432c6c:0-behzad-aghazadeh-holds-board-seat-at-scribe-therapeutics-with-16-37-stake", "tier": "direct", "title": "Behzad Aghazadeh Holds Board Seat at Scribe Therapeutics with 16.37% Stake", "topics": ["Finance", "Financial Markets", "IPO", "Life Sciences"], "summary": "Behzad Aghazadeh, through funds managed by Avoro, disclosed a 16.37% beneficial stake in Scribe Therapeutics, Inc. (SCTX) via a Schedule 13D filing on July 30, 2026. This stake includes IPO purchases, converted preferred shares, and open-market buys, with Aghazadeh also serving on Scribe's board. The funds hold the shares for investment purposes and have agreed to a 180-day lock-up period, extended until September 28, 2026.", "age_days": 17.8, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.tradingview.com/news/tradingview:5a18ca4432c6c:0-behzad-aghazadeh-holds-board-seat-at-scribe-therapeutics-with-16-37-stake", "source_name": "TradingView", "published_at": "2026-07-30T09:12:41", "tone_signals": ["Business expansion"], "company_focus": 1.0, "freshness_pct": 17.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.019534, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "30 Jul 2026 09:12", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNQ1E1bmRmQXdPd1pfYUI5OWxsb0VCaTJjSHdFejNKd2J6eU9TM2E2QmZvVEwtVUZIb3ExMVkydTR1akNzODNDemJCZ251MEk2MTBBeGJjbGM3NHlHRXVwZ1N4cWxjR0FMckJvaXZWMkFtQnA4YnNOZVdMcTEyN1JsdGsxYzVHakIxeU5ERFZhSnlUQV9rRExwYjdhdkdKbFNIMlFSNWs5cVgxb185NVplak9IWmQwZlZKNzhlMEFLRjViaWlKdkZnS3d3?oc=5", "tier": "direct", "title": "Scribe Therapeutics (SCTX): Avoro group reports 16.37% ownership after IPO", "topics": [], "summary": "", "age_days": 17.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNQ1E1bmRmQXdPd1pfYUI5OWxsb0VCaTJjSHdFejNKd2J6eU9TM2E2QmZvVEwtVUZIb3ExMVkydTR1akNzODNDemJCZ251MEk2MTBBeGJjbGM3NHlHRXVwZ1N4cWxjR0FMckJvaXZWMkFtQnA4YnNOZVdMcTEyN1JsdGsxYzVHakIxeU5ERFZhSnlUQV9rRExwYjdhdkdKbFNIMlFSNWs5cVgxb185NVplak9IWmQwZlZKNzhlMEFLRjViaWlKdkZnS3d3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-30T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000108, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "30 Jul 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMVhBaHlOQ0QydS1wMlNlVi1JRnVlTTNBRVk5ejlTdHJOUGdQeGdRcnJIckEydVd4NGFxZXh5eE5NSC1kOTRZSlAyT210N1BERHI1a3FjM1poaTlyOHV3eWNWRWhRbkhrRnZCZUVrell0bEhaOFNFOWNmd1BMa2xFUl9hbFdCanlnTFZUaXdSSTh3S0trbmprVHJUa3o5WHI3NDNPczE1VmwzcXl4NVNJMWV4MS1OVzUwbDVldnY4U2tIdzJ0NDhLYnNB?oc=5", "tier": "direct", "title": "Eli Lilly (SCTX partner) reports 7.36% equity stake in Scribe Therapeutics", "topics": [], "summary": "", "age_days": 17.9, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMVhBaHlOQ0QydS1wMlNlVi1JRnVlTTNBRVk5ejlTdHJOUGdQeGdRcnJIckEydVd4NGFxZXh5eE5NSC1kOTRZSlAyT210N1BERHI1a3FjM1poaTlyOHV3eWNWRWhRbkhrRnZCZUVrell0bEhaOFNFOWNmd1BMa2xFUl9hbFdCanlnTFZUaXdSSTh3S0trbmprVHJUa3o5WHI3NDNPczE1VmwzcXl4NVNJMWV4MS1OVzUwbDVldnY4U2tIdzJ0NDhLYnNB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-30T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 17.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.012591, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "30 Jul 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9uTDRqc3l0Rjk0XzBLeExtRWFta3FkVFF6Z3lIdW5EUGp2cUlxUkRIYWI2NnZVUTh1WEEyOUFPQ3pxZ1F3R1dqY1RKWE9uUUxUNGEtdVRsVEVzWVVWNlU3dnBvRjFtbWRKaGxBdkg4Vmc5Q3FxMkFv?oc=5", "tier": "direct", "title": "Scribe Therapeutics Inc. Revenue Breakdown \u2013 NASDAQ:SCTX", "topics": [], "summary": "", "age_days": 20.6, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9uTDRqc3l0Rjk0XzBLeExtRWFta3FkVFF6Z3lIdW5EUGp2cUlxUkRIYWI2NnZVUTh1WEEyOUFPQ3pxZ1F3R1dqY1RKWE9uUUxUNGEtdVRsVEVzWVVWNlU3dnBvRjFtbWRKaGxBdkg4Vmc5Q3FxMkFv?oc=5", "source_name": "TradingView", "published_at": "2026-07-27T14:18:15+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 5.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.00474, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 14:18", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPdWYwZUhkY1N1YkNmSUxuNExJLVRLQUdXYlRWOXUzb0FvQkNqNzNWUXVfcjVpUjNwYm5BNDV1R280QVBTa1ZyX1RXRUJDSEFJX0kzUU83NWk1QVNwSENSblg2R2YwdjZ1bTRZbUhjYi1SS05ubE4xZ0ZVMUJleHVQRWprRTEtcC1LRTViZk9nTk5KV1hlSV8yRXR2REY?oc=5", "tier": "direct", "title": "Price to earnings ratio of Scribe Therapeutics Inc. \u2013 NASDAQ:SCTX", "topics": [], "summary": "", "age_days": 20.6, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPdWYwZUhkY1N1YkNmSUxuNExJLVRLQUdXYlRWOXUzb0FvQkNqNzNWUXVfcjVpUjNwYm5BNDV1R280QVBTa1ZyX1RXRUJDSEFJX0kzUU83NWk1QVNwSENSblg2R2YwdjZ1bTRZbUhjYi1SS05ubE4xZ0ZVMUJleHVQRWprRTEtcC1LRTViZk9nTk5KV1hlSV8yRXR2REY?oc=5", "source_name": "TradingView", "published_at": "2026-07-27T14:11:19+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 5.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.004736, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 14:11", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQN0dYM2RrWnVuZE01aDdWSFlKTkV5R2RNVmlWT2Y2NHVtcU9aVFA2TmRFTkJETHNoYkNjbnpwdnF5MTk0cE1CY3JoVjM5YUNoa3NlQUQwaVlFem90LTNxVWFCZElpTk04d2F4LU9MOFo1VUtPejNZOWZHdDlHcm9qRXI4ZTJfRHNFZThkZTVpd2FLT0g3UFZOYm95SGZLVVptTmRoVnFQUlZNNm1KVWJWTmctRi1zRW11OHhV?oc=5", "tier": "direct", "title": "Scribe Therapeutics IPO closes as Sanofi buys 500K shares", "topics": [], "summary": "", "age_days": 20.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQN0dYM2RrWnVuZE01aDdWSFlKTkV5R2RNVmlWT2Y2NHVtcU9aVFA2TmRFTkJETHNoYkNjbnpwdnF5MTk0cE1CY3JoVjM5YUNoa3NlQUQwaVlFem90LTNxVWFCZElpTk04d2F4LU9MOFo1VUtPejNZOWZHdDlHcm9qRXI4ZTJfRHNFZThkZTVpd2FLT0g3UFZOYm95SGZLVVptTmRoVnFQUlZNNm1KVWJWTmctRi1zRW11OHhV?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-27T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3.8e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/scribe-therapeutics-announces-closing-initial-200500827.html", "tier": "direct", "title": "Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement", "topics": ["IPO", "Life Sciences", "Finance"], "summary": "Scribe Therapeutics Inc. announced the closing of its upsized initial public offering of 9,867,000 shares at $15.00 per share, which included the full exercise of the underwriters' option for additional shares. Concurrently, the company also completed a private placement of 500,000 shares to Sanofi. The total gross proceeds from the IPO and private placement amounted to approximately $155.51 million.", "age_days": 20.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/scribe-therapeutics-announces-closing-initial-200500827.html", "source_name": "Market source", "published_at": "2026-07-27T05:41:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3.1e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "27 Jul 2026 05:41", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.wsj.com/pro/venture-capital/jennifer-doudnas-scribe-therapeutics-rockets-at-ipo-4654f4cd", "tier": "direct", "title": "Jennifer Doudna\u2019s Scribe Therapeutics Rockets at IPO", "topics": ["Financial Markets", "IPO", "Life Sciences"], "summary": "Scribe Therapeutics, co-founded by Nobel laureate Jennifer Doudna, saw its shares jump 44.3% on its first day of trading. The genetic-medicines company raised $128.7 million in its IPO, selling over 8.5 million shares at $15 each. This successful debut signals a continued rebound for biotech IPOs this year.", "age_days": 21.2, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "editorial_wire", "source_link": "https://www.wsj.com/pro/venture-capital/jennifer-doudnas-scribe-therapeutics-rockets-at-ipo-4654f4cd", "source_name": "WSJ", "published_at": "2026-07-26T23:11:13", "tone_signals": ["Large positive market reaction", "Positive market reaction"], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 62, "evidence_basis": "archived_article", "evidence_share": 100.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.00015, "influence_label": "Medium", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 40, "published_display": "26 Jul 2026 23:11", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "100"}, {"url": "https://www.lw.com/en/news/2026/07/latham-advises-on-scribe-therapeutics-ipo", "tier": "direct", "title": "Latham Advises on Scribe Therapeutics\u2019 US$155.51 Million IPO", "topics": ["Finance", "IPO", "Life Sciences"], "summary": "Latham & Watkins LLP advised the underwriters in Scribe Therapeutics Inc.'s upsized initial public offering, which closed at US$155.51 million. The clinical-stage biotechnology company offered 9,867,000 shares at US$15 per share, including the underwriters' full exercise of their option for additional shares. Scribe Therapeutics' common stock began trading on Nasdaq under the ticker SCTX on July 24, 2026.", "age_days": 21.2, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.lw.com/en/news/2026/07/latham-advises-on-scribe-therapeutics-ipo", "source_name": "Latham & Watkins LLP", "published_at": "2026-07-26T23:11:13", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 4e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "26 Jul 2026 23:11", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.fiercebiotech.com/biotech/scribe-aims-96m-ipo-fund-clinical-push-lipid-lowering-genetic-meds", "tier": "direct", "title": "Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds", "topics": ["IPO", "Life Sciences"], "summary": "Scribe Therapeutics plans to raise $96 million through an IPO to advance its genetic medicine pipeline, including its lead program STX-1150 for lowering cholesterol, with initial data expected in the first half of 2027. The company will allocate significant funds to clinical development of STX-1150 and other cardiovascular candidates, STX-1400 and STX-1200, which target APOC3 and LPA genes respectively. Big pharmaceutical partners like Sanofi and Eli Lilly are also involved, with Sanofi committing to purchase $7.5 million in stock.", "age_days": 23.7, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.fiercebiotech.com/biotech/scribe-aims-96m-ipo-fund-clinical-push-lipid-lowering-genetic-meds", "source_name": "Fierce Biotech", "published_at": "2026-07-24T12:41:35", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 1.1e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "24 Jul 2026 12:41", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQT0tSSzEzQi1oMjdyZjRlVEJoUS1jakJndHBxczBMRUptYzUyUlN3aTg1REhBX3Z4d3lJS2xVanZ3c0ZpMl84THctZUxhY3lORWphSVdkY0JqQmliY3BJVEU4dm1HNVFRYnY4UmR1ZWIybjJMNnBHeTFfbXNlNGI5X2s5ZFhvNHlOeWgxLTNVWm5USklKWVRCeE5SclNUekgxYUhsZkVn?oc=5", "tier": "direct", "title": "Scribe Therapeutics, Inc. SEC Filing (Jul 24, 2026)", "topics": [], "summary": "", "age_days": 23.9, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQT0tSSzEzQi1oMjdyZjRlVEJoUS1jakJndHBxczBMRUptYzUyUlN3aTg1REhBX3Z4d3lJS2xVanZ3c0ZpMl84THctZUxhY3lORWphSVdkY0JqQmliY3BJVEU4dm1HNVFRYnY4UmR1ZWIybjJMNnBHeTFfbXNlNGI5X2s5ZFhvNHlOeWgxLTNVWm5USklKWVRCeE5SclNUekgxYUhsZkVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-24T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 1.6e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "24 Jul 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.fiercebiotech.com/biotech/scribe-records-upsized-129m-ipo-latest-biotech-stock-market-debut", "tier": "direct", "title": "Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds", "topics": ["IPO", "Life Sciences"], "summary": "Scribe Therapeutics has successfully upsized its IPO, raising $128.7 million to advance its gene-editing pipeline focused on lipid-lowering therapies. The company's lead candidate, STX-1150, targets the PCSK9 gene for cardiovascular disease, with topline data expected in the first half of 2027. Scribe plans to use the proceeds to fund clinical trials for STX-1150, STX-1400, and STX-1200, aiming to offer personalized genetic medicine options for patients.", "age_days": 24.0, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.fiercebiotech.com/biotech/scribe-records-upsized-129m-ipo-latest-biotech-stock-market-debut", "source_name": "Fierce Biotech", "published_at": "2026-07-24T04:00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 1.2e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "24 Jul 2026 04:00", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.globenewswire.com/news-release/2026/07/24/3332675/0/en/Scribe-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html", "tier": "direct", "title": "Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering", "topics": ["Biotech", "Crispr", "Genetic Medicine", "Initial Public Offering", "Initial Public Offerings", "IPO"], "summary": "ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (\u201cScribe Therapeutics\u201d) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial public offering of 8,580,000 shares of its common stock at the high end of the range at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other of", "age_days": 24.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/07/24/3332675/0/en/Scribe-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html", "source_name": "globenewswire.com", "published_at": "2026-07-24T01:08:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 1.6e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "24 Jul 2026 01:08", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/scribe-secures-129m-rare-gene-211800640.html", "tier": "direct", "title": "Scribe secures $129M in a rare gene editing IPO", "topics": ["Biotech", "Gene Editing", "Initial Public Offering", "IPO"], "summary": "This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Scribe Therapeutics has raised close to $129 millionin the first initial public offering for a developer of gene editing medicines in more than two years. The startup on Thursday sold 8.58 million shares at $15 apiece, topping projections set earlier this week. Shares will begin trading Friday on the Nasdaq stock exchange under the ticker symbol \"SCTX.\" Biotech IPOs have been on an upswing in 2026. Including Scribe's offering, 14 companies have price", "age_days": 24.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/scribe-secures-129m-rare-gene-211800640.html", "source_name": "finance.yahoo.com", "published_at": "2026-07-23T21:18:00+00:00", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 1.7e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Jul 2026 21:18", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE5pR3NWa2dyendscW05RG1SRFhTdnI5V1g5MDg4X19KS25xTTJiUWJiSEFPRks3X0JTc2otVVZrUjlfd1pOeEtlem5WdFdpOFdTbkJjNA?oc=5", "tier": "direct", "title": "Scribe Therapeutics (SCTX) Stock Analysis Report | Financials & Insights", "topics": [], "summary": "", "age_days": 0.2, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "e23189ce97440ba8c3eb9af2d2a4e2d464702395dc3af578b01e3ccfcf9d0c6f", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE5pR3NWa2dyendscW05RG1SRFhTdnI5V1g5MDg4X19KS25xTTJiUWJiSEFPRks3X0JTc2otVVZrUjlfd1pOeEtlem5WdFdpOFdTbkJjNA?oc=5", "source_name": "Benzinga", "published_at": "2026-08-17T00:44:57+00:00", "source_names": ["Benzinga"], "target_scope": "", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": false, "freshness_pct": 94.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.06905, "influence_label": "None", "provider_symbol": "", "relevance_score": null, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": [], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "17 Aug 2026 00:44", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE8yRXBrQjdLRzk0Wk9OQzVYOXdyMXhvejdUekZfTG85NXRoQjcwQlExYm1JMG9XNEZxS011Xy1tWEpEVGFvVXVkVDc0cVNtU0Yya0ZCZS1QNGZOVWI4S3ZwRnl6dUJUZG5sYUYxQw?oc=5", "tier": "direct", "title": "Should I buy Scribe Therapeutics Inc. (SCTX)", "topics": [], "summary": "", "age_days": 1.0, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "16b717577e0dc8b398de2a0c894f9c82f171fe9fb4cfee6b6b287165ec8b4694", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMibEFVX3lxTE8yRXBrQjdLRzk0Wk9OQzVYOXdyMXhvejdUekZfTG85NXRoQjcwQlExYm1JMG9XNEZxS011Xy1tWEpEVGFvVXVkVDc0cVNtU0Yya0ZCZS1QNGZOVWI4S3ZwRnl6dUJUZG5sYUYxQw?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-08-16T04:38:46+00:00", "source_names": ["Zacks Investment Research"], "target_scope": "Should I buy Scribe Therapeutics Inc. (SCTX)", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 71.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.044266, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "16 Aug 2026 04:38", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9HWXFrSHg3NGx0dWloNEVrUGJUUHFYSGc4THZ0cldjaWdMM01IbGhEWW1UMHVNNmdWay1vNWw4QVVzY19fUFEzWnpiQ0tOVk1xSjZ2VzNvcUdSUEhxdlFWR1hrSmFBOVFFUWc?oc=5", "tier": "direct", "title": "What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement", "topics": [], "summary": "", "age_days": 1.3, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "36863b4954e7bc8436a6cccd9aee40dc836fb06bb6e969cd91e80f13f2be929b", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiakFVX3lxTE9HWXFrSHg3NGx0dWloNEVrUGJUUHFYSGc4THZ0cldjaWdMM01IbGhEWW1UMHVNNmdWay1vNWw4QVVzY19fUFEzWnpiQ0tOVk1xSjZ2VzNvcUdSUEhxdlFWR1hrSmFBOVFFUWc?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-08-15T20:02:04+00:00", "source_names": ["Zacks Investment Research"], "target_scope": "", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": false, "freshness_pct": 82.9, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.092896, "influence_label": "None", "provider_symbol": "", "relevance_score": null, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": [], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "15 Aug 2026 20:02", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "", "provider_directional_mass": null}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-fecef9420a3a.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX) awards 14,725 stock options to director Bleharski", "topics": ["Finance", "Life Sciences"], "summary": "Scribe Therapeutics (SCTX) director Joshua Bleharski was granted 14,725 stock options with an exercise price of $15.00 per share, expiring on July 22, 2036. The options will vest in three equal annual installments on July 23 of 2027, 2028, and 2029, contingent on his continued service to the company. This transaction is classified as a compensation award, not a market purchase.", "age_days": 3.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "6e34106da6a64dc54e4b70050dbf395f0891059c647be35a2730ae6c3f2e610e", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-fecef9420a3a.html", "source_name": "Stock Titan", "published_at": "2026-08-13T12:41:35", "source_names": ["Stock Titan"], "target_scope": "Scribe Therapeutics (SCTX) awards 14,725 stock options to director Bleharski Scribe Therapeutics (SCTX) director Joshua Bleharski was granted 14,725 stock options with an exercise price of $15.00 per share, expiring on July 22, 2036.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 28.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.017582, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "13 Aug 2026 12:41", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.0475}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/schedule-13d-scribe-therapeutics-inc-major-shareholder-acquisition-5-de46eae4702d.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX): Avoro group reports 16.37% ownership after IPO", "topics": ["Finance", "IPO", "Life Sciences"], "summary": "Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have reported a collective beneficial ownership of 16.37% in Scribe Therapeutics, Inc. (SCTX) common stock following the company's IPO. This stake, totaling 3,088,888 shares, arose from the conversion of Series B preferred stock, purchases during the IPO, and open-market transactions. The entities are subject to customary lock-up agreements and registration rights.", "age_days": 4.9, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "14e56755505ff4cd709c74568acfdff4ade5502f3abb26f73638f0c37422fafd", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/schedule-13d-scribe-therapeutics-inc-major-shareholder-acquisition-5-de46eae4702d.html", "source_name": "Stock Titan", "published_at": "2026-08-12T05:41:00", "source_names": ["Stock Titan"], "target_scope": "Scribe Therapeutics (SCTX): Avoro group reports 16.37% ownership after IPO Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have reported a collective beneficial ownership of 16.37% in Scribe Therapeutics, Inc. (SCTX) common stock following the company's IPO. This stake, totaling 3,088,888 shares, arose from the conversion of Series B preferred stock, purchases during the IPO, and open-market transactions.", "tone_signals": ["Business expansion"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 61.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.069747, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.527, "provider_symbols": ["SCTX"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Aug 2026 05:41", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.1073}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-d5d81f63441d.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX) CFO gets major option grants and family share buys", "topics": ["Finance", "IPO", "Life Sciences"], "summary": "Scribe Therapeutics CFO David Parrot received significant equity awards, including time-vested and performance-based stock options totaling over 200,000 shares, both priced at $15.00. He also reported indirect open-market purchases of 2,666 common shares for family members at the same price. These transactions follow a prior option grant disclosed in connection with the company's initial public offering.", "age_days": 5.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "f4cb64f3e8286ffb600569fe8d382717519712b40cffee28c9f7928dc351b48a", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-d5d81f63441d.html", "source_name": "Stock Titan", "published_at": "2026-08-11T19:40:24", "source_names": ["Stock Titan"], "target_scope": "Scribe Therapeutics (SCTX) CFO gets major option grants and family share buys Scribe Therapeutics CFO David Parrot received significant equity awards, including time-vested and performance-based stock options totaling over 200,000 shares, both priced at $15.00. He also reported indirect open-market purchases of 2,666 common shares for family members at the same price.", "tone_signals": ["Business expansion"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 15.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.01281, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.527, "provider_symbols": ["SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Aug 2026 19:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.4304}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-1e8d36b8c544.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX) CEO receives time- and performance-based option grants", "topics": ["Finance", "IPO", "Life Sciences"], "summary": "Scribe Therapeutics CEO Benjamin L. Oakes received three option awards for the company's common stock. These include a fully vested grant of 12,969 options on March 13, 2026, and two grants on July 23, 2026: a time-based option for 264,784 shares vesting monthly over four years, and a performance-based option for 429,599 shares contingent on market-based performance criteria. The filing also provides details on vesting schedules, exercise prices, and expiration dates for these grants.", "age_days": 5.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "ebc7e2a580aa1762505e13f424efa86864758f5991b4f13f0a201a4a728417ae", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/form-4-scribe-therapeutics-inc-insider-trading-activity-1e8d36b8c544.html", "source_name": "Stock Titan", "published_at": "2026-08-11T19:40:24", "source_names": ["Stock Titan"], "target_scope": "Scribe Therapeutics (SCTX) CEO receives time- and performance-based option grants Scribe Therapeutics CEO Benjamin L. Oakes received three option awards for the company's common stock.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 15.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.009723, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Aug 2026 19:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.1023}, {"url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQaHJRblljWVRnakc4ZW9qa1ZabS1NOHU5SDBCYzVnRVFxV3VrRnNMSUVGX1JOTmhPNTRpbTUwN1VCSkRTS3lzdDhycXkzcHBFWVR3a05lRDByWFEzWGhaVnB3ME1CVnFTQ0pXMDdjbHVJdTdWYmVGR2JTY1N6R0M2d2ItWWptMnJXYzBXVmJHOVkza2ZiRVhpX194bFJ5NjRrZVE4aWpSb1dZRzBrb1RGMllYX2Fqa0tn?oc=5", "tier": "direct", "title": "Scribe Therapeutics (SCTX) grants 14,725 options to Aghazadeh and Avoro entities", "topics": [], "summary": "", "age_days": 6.4, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "aa54875925c98e48805ade8ed78616bcdc3f150c72e0227a3fb28263ba747196", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQaHJRblljWVRnakc4ZW9qa1ZabS1NOHU5SDBCYzVnRVFxV3VrRnNMSUVGX1JOTmhPNTRpbTUwN1VCSkRTS3lzdDhycXkzcHBFWVR3a05lRDByWFEzWGhaVnB3ME1CVnFTQ0pXMDdjbHVJdTdWYmVGR2JTY1N6R0M2d2ItWWptMnJXYzBXVmJHOVkza2ZiRVhpX194bFJ5NjRrZVE4aWpSb1dZRzBrb1RGMllYX2Fqa0tn?oc=5", "source_name": "Stock Titan", "published_at": "2026-08-10T20:00:12+00:00", "source_names": ["Stock Titan"], "target_scope": "Scribe Therapeutics (SCTX) grants 14,725 options to Aghazadeh and Avoro entities", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 11.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.00592, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 20:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.stocktitan.net/sec-filings/SCTX/form-3-scribe-therapeutics-inc-initial-statement-of-beneficial-owners-418b6a014f13.html", "tier": "direct", "title": "Scribe Therapeutics (SCTX) ten percent owner Brett Staahl reports stock and option holdings", "topics": ["Finance", "Life Sciences"], "summary": "Scribe Therapeutics (SCTX) ten percent owner Brett Staahl has filed an initial statement of beneficial ownership, reporting 524,336 shares of Common Stock held directly. Additionally, Staahl holds four stock option awards with various exercise prices and expiration dates ranging from 2030 to 2036, covering a total of 26,703 underlying shares. Some of these options are fully vested, while others have a vesting schedule that began on January 1, 2026.", "age_days": 6.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "23a0246c8115b3bdceaa888e57a56e7d44ea4f3531f94c16667d429aa8b2b6da", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/SCTX/form-3-scribe-therapeutics-inc-initial-statement-of-beneficial-owners-418b6a014f13.html", "source_name": "Stock Titan", "published_at": "2026-08-10T17:40:28", "source_names": ["Stock Titan"], "target_scope": "Scribe Therapeutics (SCTX) ten percent owner Brett Staahl reports stock and option holdings Scribe Therapeutics (SCTX) ten percent owner Brett Staahl has filed an initial statement of beneficial ownership, reporting 524,336 shares of Common Stock held directly. Additionally, Staahl holds four stock option awards with various exercise prices and expiration dates ranging from 2030 to 2036, covering a total of 26,703 underlying shares.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 10.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.00668, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 17:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.0352}, {"url": "https://www.tradingview.com/symbols/NASDAQ-SCTX/financials-cash-flow/free-cash-flow", "tier": "direct", "title": "Free cash flow of Scribe Therapeutics Inc. \u2013 NASDAQ:SCTX", "topics": ["Earnings", "Life Sciences"], "summary": "This article provides a brief mention of the free cash flow for Scribe Therapeutics Inc. (NASDAQ: SCTX) as found on TradingView. It appears to be a financial data point without further analysis or details within the snippet provided. The primary content available is navigational and structural information related to the TradingView platform.", "age_days": 11.2, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "857dc8f5cedd71e12959646c4357f1a7fecedc3dff8ce5f6812ec557da90a0cf", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.tradingview.com/symbols/NASDAQ-SCTX/financials-cash-flow/free-cash-flow", "source_name": "TradingView", "published_at": "2026-08-05T23:11:13", "source_names": ["TradingView"], "target_scope": "Free cash flow of Scribe Therapeutics Inc. \u2013 NASDAQ:SCTX This article provides a brief mention of the free cash flow for Scribe Therapeutics Inc. (NASDAQ: SCTX) as found on TradingView.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 21.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.020272, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "05 Aug 2026 23:11", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.0254}, {"url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9iVDF6WFNnRnZPVU95cjRPcTFDSGt5UGhoS0w1UjNjSmN2QmlBTnpNd2trUmgwZFFqZG4wdlNUR282X1pJM3FhT2R5bVZWVm01eTR1VU5KeEVObmxod3dOVVpvMzZJRERTaE5iYnUxUQ?oc=5", "tier": "direct", "title": "Scribe Therapeutics Inc. (SCTX) Revenue (TTM)", "topics": [], "summary": "", "age_days": 13.8, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "a2cda3fce8bcfead5a9f63da772012644abc5289ccb61f10a5834ab21d5d1bb4", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9iVDF6WFNnRnZPVU95cjRPcTFDSGt5UGhoS0w1UjNjSmN2QmlBTnpNd2trUmgwZFFqZG4wdlNUR282X1pJM3FhT2R5bVZWVm01eTR1VU5KeEVObmxod3dOVVpvMzZJRERTaE5iYnUxUQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-08-03T08:37:25+00:00", "source_names": ["Zacks Investment Research"], "target_scope": "Scribe Therapeutics Inc. (SCTX) Revenue (TTM)", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 14.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.014122, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "03 Aug 2026 08:37", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.tradingview.com/news/tradingview:5a18ca4432c6c:0-behzad-aghazadeh-holds-board-seat-at-scribe-therapeutics-with-16-37-stake", "tier": "direct", "title": "Behzad Aghazadeh Holds Board Seat at Scribe Therapeutics with 16.37% Stake", "topics": ["Finance", "Financial Markets", "IPO", "Life Sciences"], "summary": "Behzad Aghazadeh, through funds managed by Avoro, disclosed a 16.37% beneficial stake in Scribe Therapeutics, Inc. (SCTX) via a Schedule 13D filing on July 30, 2026. This stake includes IPO purchases, converted preferred shares, and open-market buys, with Aghazadeh also serving on Scribe's board. The funds hold the shares for investment purposes and have agreed to a 180-day lock-up period, extended until September 28, 2026.", "age_days": 17.8, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "3e52782e92e528cd4b3178afabfd675ea0dd73e5d45ed4b0c5e64d6300afda1f", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.tradingview.com/news/tradingview:5a18ca4432c6c:0-behzad-aghazadeh-holds-board-seat-at-scribe-therapeutics-with-16-37-stake", "source_name": "TradingView", "published_at": "2026-07-30T09:12:41", "source_names": ["TradingView"], "target_scope": "Behzad Aghazadeh Holds Board Seat at Scribe Therapeutics with 16.37% Stake Behzad Aghazadeh, through funds managed by Avoro, disclosed a 16.37% beneficial stake in Scribe Therapeutics, Inc. (SCTX) via a Schedule 13D filing on July 30, 2026. This stake includes IPO purchases, converted preferred shares, and open-market buys, with Aghazadeh also serving on Scribe's board.", "tone_signals": ["Business expansion"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 17.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.019534, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.527, "provider_symbols": ["SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "30 Jul 2026 09:12", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.3423}, {"url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNQ1E1bmRmQXdPd1pfYUI5OWxsb0VCaTJjSHdFejNKd2J6eU9TM2E2QmZvVEwtVUZIb3ExMVkydTR1akNzODNDemJCZ251MEk2MTBBeGJjbGM3NHlHRXVwZ1N4cWxjR0FMckJvaXZWMkFtQnA4YnNOZVdMcTEyN1JsdGsxYzVHakIxeU5ERFZhSnlUQV9rRExwYjdhdkdKbFNIMlFSNWs5cVgxb185NVplak9IWmQwZlZKNzhlMEFLRjViaWlKdkZnS3d3?oc=5", "tier": "direct", "title": "Scribe Therapeutics (SCTX): Avoro group reports 16.37% ownership after IPO", "topics": [], "summary": "", "age_days": 17.9, "is_stale": false, "provider": "archive", "providers": ["archive", "google_news"], "sentiment": "neutral", "story_key": "14e56755505ff4cd709c74568acfdff4ade5502f3abb26f73638f0c37422fafd", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNQ1E1bmRmQXdPd1pfYUI5OWxsb0VCaTJjSHdFejNKd2J6eU9TM2E2QmZvVEwtVUZIb3ExMVkydTR1akNzODNDemJCZ251MEk2MTBBeGJjbGM3NHlHRXVwZ1N4cWxjR0FMckJvaXZWMkFtQnA4YnNOZVdMcTEyN1JsdGsxYzVHakIxeU5ERFZhSnlUQV9rRExwYjdhdkdKbFNIMlFSNWs5cVgxb185NVplak9IWmQwZlZKNzhlMEFLRjViaWlKdkZnS3d3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-30T07:00:00+00:00", "source_names": ["Stock Titan"], "target_scope": "Scribe Therapeutics (SCTX): Avoro group reports 16.37% ownership after IPO", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.000108, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "30 Jul 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMVhBaHlOQ0QydS1wMlNlVi1JRnVlTTNBRVk5ejlTdHJOUGdQeGdRcnJIckEydVd4NGFxZXh5eE5NSC1kOTRZSlAyT210N1BERHI1a3FjM1poaTlyOHV3eWNWRWhRbkhrRnZCZUVrell0bEhaOFNFOWNmd1BMa2xFUl9hbFdCanlnTFZUaXdSSTh3S0trbmprVHJUa3o5WHI3NDNPczE1VmwzcXl4NVNJMWV4MS1OVzUwbDVldnY4U2tIdzJ0NDhLYnNB?oc=5", "tier": "direct", "title": "Eli Lilly (SCTX partner) reports 7.36% equity stake in Scribe Therapeutics", "topics": [], "summary": "", "age_days": 17.9, "is_stale": false, "provider": "archive", "providers": ["archive", "google_news"], "sentiment": "neutral", "story_key": "981f963d56a099756905be60820f1d7ffba44fa378dad672824d788389233198", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMVhBaHlOQ0QydS1wMlNlVi1JRnVlTTNBRVk5ejlTdHJOUGdQeGdRcnJIckEydVd4NGFxZXh5eE5NSC1kOTRZSlAyT210N1BERHI1a3FjM1poaTlyOHV3eWNWRWhRbkhrRnZCZUVrell0bEhaOFNFOWNmd1BMa2xFUl9hbFdCanlnTFZUaXdSSTh3S0trbmprVHJUa3o5WHI3NDNPczE1VmwzcXl4NVNJMWV4MS1OVzUwbDVldnY4U2tIdzJ0NDhLYnNB?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-30T07:00:00+00:00", "source_names": ["Stock Titan"], "target_scope": "Eli Lilly (SCTX partner) reports 7.36% equity stake in Scribe Therapeutics", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 17.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.012591, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "30 Jul 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9uTDRqc3l0Rjk0XzBLeExtRWFta3FkVFF6Z3lIdW5EUGp2cUlxUkRIYWI2NnZVUTh1WEEyOUFPQ3pxZ1F3R1dqY1RKWE9uUUxUNGEtdVRsVEVzWVVWNlU3dnBvRjFtbWRKaGxBdkg4Vmc5Q3FxMkFv?oc=5", "tier": "direct", "title": "Scribe Therapeutics Inc. Revenue Breakdown \u2013 NASDAQ:SCTX", "topics": [], "summary": "", "age_days": 20.6, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "add7a20127a2c8287a548f5b2cd0b56d6e5b4e6ebdb555f4c56a77e5fa9abd0e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9uTDRqc3l0Rjk0XzBLeExtRWFta3FkVFF6Z3lIdW5EUGp2cUlxUkRIYWI2NnZVUTh1WEEyOUFPQ3pxZ1F3R1dqY1RKWE9uUUxUNGEtdVRsVEVzWVVWNlU3dnBvRjFtbWRKaGxBdkg4Vmc5Q3FxMkFv?oc=5", "source_name": "TradingView", "published_at": "2026-07-27T14:18:15+00:00", "source_names": ["TradingView"], "target_scope": "Scribe Therapeutics Inc. Revenue Breakdown \u2013 NASDAQ:SCTX", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 5.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.00474, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 14:18", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPdWYwZUhkY1N1YkNmSUxuNExJLVRLQUdXYlRWOXUzb0FvQkNqNzNWUXVfcjVpUjNwYm5BNDV1R280QVBTa1ZyX1RXRUJDSEFJX0kzUU83NWk1QVNwSENSblg2R2YwdjZ1bTRZbUhjYi1SS05ubE4xZ0ZVMUJleHVQRWprRTEtcC1LRTViZk9nTk5KV1hlSV8yRXR2REY?oc=5", "tier": "direct", "title": "Price to earnings ratio of Scribe Therapeutics Inc. \u2013 NASDAQ:SCTX", "topics": [], "summary": "", "age_days": 20.6, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "38f21c1849831e4c067a36c6bee62156ff2b80c8c6bccc1fb01de6a15306306f", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPdWYwZUhkY1N1YkNmSUxuNExJLVRLQUdXYlRWOXUzb0FvQkNqNzNWUXVfcjVpUjNwYm5BNDV1R280QVBTa1ZyX1RXRUJDSEFJX0kzUU83NWk1QVNwSENSblg2R2YwdjZ1bTRZbUhjYi1SS05ubE4xZ0ZVMUJleHVQRWprRTEtcC1LRTViZk9nTk5KV1hlSV8yRXR2REY?oc=5", "source_name": "TradingView", "published_at": "2026-07-27T14:11:19+00:00", "source_names": ["TradingView"], "target_scope": "Price to earnings ratio of Scribe Therapeutics Inc. \u2013 NASDAQ:SCTX", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 5.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.004736, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 14:11", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQN0dYM2RrWnVuZE01aDdWSFlKTkV5R2RNVmlWT2Y2NHVtcU9aVFA2TmRFTkJETHNoYkNjbnpwdnF5MTk0cE1CY3JoVjM5YUNoa3NlQUQwaVlFem90LTNxVWFCZElpTk04d2F4LU9MOFo1VUtPejNZOWZHdDlHcm9qRXI4ZTJfRHNFZThkZTVpd2FLT0g3UFZOYm95SGZLVVptTmRoVnFQUlZNNm1KVWJWTmctRi1zRW11OHhV?oc=5", "tier": "direct", "title": "Scribe Therapeutics IPO closes as Sanofi buys 500K shares", "topics": [], "summary": "", "age_days": 20.9, "is_stale": false, "provider": "archive", "providers": ["archive", "google_news"], "sentiment": "neutral", "story_key": "03568f6c9d6b3dad9460edfcbce85017717cb706d1ef0543f425e2cebbcdd6e7", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQN0dYM2RrWnVuZE01aDdWSFlKTkV5R2RNVmlWT2Y2NHVtcU9aVFA2TmRFTkJETHNoYkNjbnpwdnF5MTk0cE1CY3JoVjM5YUNoa3NlQUQwaVlFem90LTNxVWFCZElpTk04d2F4LU9MOFo1VUtPejNZOWZHdDlHcm9qRXI4ZTJfRHNFZThkZTVpd2FLT0g3UFZOYm95SGZLVVptTmRoVnFQUlZNNm1KVWJWTmctRi1zRW11OHhV?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-27T07:00:00+00:00", "source_names": ["Stock Titan"], "target_scope": "Scribe Therapeutics IPO closes as Sanofi buys 500K shares", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 3.8e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Jul 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/scribe-therapeutics-announces-closing-initial-200500827.html", "tier": "direct", "title": "Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement", "topics": ["IPO", "Life Sciences", "Finance"], "summary": "Scribe Therapeutics Inc. announced the closing of its upsized initial public offering of 9,867,000 shares at $15.00 per share, which included the full exercise of the underwriters' option for additional shares. Concurrently, the company also completed a private placement of 500,000 shares to Sanofi. The total gross proceeds from the IPO and private placement amounted to approximately $155.51 million.", "age_days": 20.9, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "fddeaad3c9b6c9f8bb3b48b6ce1a64a10eb9bb7d6ef7c0e63e92a4c0dac985d1", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/scribe-therapeutics-announces-closing-initial-200500827.html", "source_name": "Market source", "published_at": "2026-07-27T05:41:00", "source_names": ["Market source"], "target_scope": "Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement Scribe Therapeutics Inc.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 3.1e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["GS", "LLY", "SCTX", "WFC"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "27 Jul 2026 05:41", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.5078}, {"url": "https://www.wsj.com/pro/venture-capital/jennifer-doudnas-scribe-therapeutics-rockets-at-ipo-4654f4cd", "tier": "direct", "title": "Jennifer Doudna\u2019s Scribe Therapeutics Rockets at IPO", "topics": ["Financial Markets", "IPO", "Life Sciences"], "summary": "Scribe Therapeutics, co-founded by Nobel laureate Jennifer Doudna, saw its shares jump 44.3% on its first day of trading. The genetic-medicines company raised $128.7 million in its IPO, selling over 8.5 million shares at $15 each. This successful debut signals a continued rebound for biotech IPOs this year.", "age_days": 21.2, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "721ce88d4863fd3ff6f6b1ff252930b81c1a85549ebe85715f53d343c9ddd4ff", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "editorial_wire", "source_link": "https://www.wsj.com/pro/venture-capital/jennifer-doudnas-scribe-therapeutics-rockets-at-ipo-4654f4cd", "source_name": "WSJ", "published_at": "2026-07-26T23:11:13", "source_names": ["WSJ"], "target_scope": "Jennifer Doudna\u2019s Scribe Therapeutics Rockets at IPO Scribe Therapeutics, co-founded by Nobel laureate Jennifer Doudna, saw its shares jump 44.3% on its first day of trading.", "tone_signals": ["Large positive market reaction", "Positive market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 62, "evidence_basis": "archived_article", "evidence_share": 100.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.00015, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.655, "provider_symbols": ["SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 40, "published_display": "26 Jul 2026 23:11", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "100", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.8338}, {"url": "https://www.lw.com/en/news/2026/07/latham-advises-on-scribe-therapeutics-ipo", "tier": "direct", "title": "Latham Advises on Scribe Therapeutics\u2019 US$155.51 Million IPO", "topics": ["Finance", "IPO", "Life Sciences"], "summary": "Latham & Watkins LLP advised the underwriters in Scribe Therapeutics Inc.'s upsized initial public offering, which closed at US$155.51 million. The clinical-stage biotechnology company offered 9,867,000 shares at US$15 per share, including the underwriters' full exercise of their option for additional shares. Scribe Therapeutics' common stock began trading on Nasdaq under the ticker SCTX on July 24, 2026.", "age_days": 21.2, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "f37d89c78c3cdf489fb311846939c3ab6d803e305a391d0f5d512cf86e6761f6", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.lw.com/en/news/2026/07/latham-advises-on-scribe-therapeutics-ipo", "source_name": "Latham & Watkins LLP", "published_at": "2026-07-26T23:11:13", "source_names": ["Latham & Watkins LLP"], "target_scope": "Latham Advises on Scribe Therapeutics\u2019 US$155.51 Million IPO Latham & Watkins LLP advised the underwriters in Scribe Therapeutics Inc.'s upsized initial public offering, which closed at US$155.51 million. Scribe Therapeutics' common stock began trading on Nasdaq under the ticker SCTX on July 24, 2026.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 4e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "26 Jul 2026 23:11", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.5358}, {"url": "https://www.fiercebiotech.com/biotech/scribe-aims-96m-ipo-fund-clinical-push-lipid-lowering-genetic-meds", "tier": "direct", "title": "Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds", "topics": ["IPO", "Life Sciences"], "summary": "Scribe Therapeutics plans to raise $96 million through an IPO to advance its genetic medicine pipeline, including its lead program STX-1150 for lowering cholesterol, with initial data expected in the first half of 2027. The company will allocate significant funds to clinical development of STX-1150 and other cardiovascular candidates, STX-1400 and STX-1200, which target APOC3 and LPA genes respectively. Big pharmaceutical partners like Sanofi and Eli Lilly are also involved, with Sanofi committing to purchase $7.5 million in stock.", "age_days": 23.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "0b8633f5e3b5d5401f101db55b9b404976d8ba8b8e5c9e30010bed2df00149a9", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.fiercebiotech.com/biotech/scribe-aims-96m-ipo-fund-clinical-push-lipid-lowering-genetic-meds", "source_name": "Fierce Biotech", "published_at": "2026-07-24T12:41:35", "source_names": ["Fierce Biotech"], "target_scope": "Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds Scribe Therapeutics plans to raise $96 million through an IPO to advance its genetic medicine pipeline, including its lead program STX-1150 for lowering cholesterol, with initial data expected in the first half of 2027. Big pharmaceutical partners like Sanofi and Eli Lilly are also involved, with Sanofi committing to purchase $7.5 million in stock.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 1.1e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["AMGN", "BIIB", "LLY", "PFE", "SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "24 Jul 2026 12:41", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.0342}, {"url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQT0tSSzEzQi1oMjdyZjRlVEJoUS1jakJndHBxczBMRUptYzUyUlN3aTg1REhBX3Z4d3lJS2xVanZ3c0ZpMl84THctZUxhY3lORWphSVdkY0JqQmliY3BJVEU4dm1HNVFRYnY4UmR1ZWIybjJMNnBHeTFfbXNlNGI5X2s5ZFhvNHlOeWgxLTNVWm5USklKWVRCeE5SclNUekgxYUhsZkVn?oc=5", "tier": "direct", "title": "Scribe Therapeutics, Inc. SEC Filing (Jul 24, 2026)", "topics": [], "summary": "", "age_days": 23.9, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "7b1a2ebeafe1a53bf8398737dde6324338654a65a21d3d0101cddab47951d13a", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQT0tSSzEzQi1oMjdyZjRlVEJoUS1jakJndHBxczBMRUptYzUyUlN3aTg1REhBX3Z4d3lJS2xVanZ3c0ZpMl84THctZUxhY3lORWphSVdkY0JqQmliY3BJVEU4dm1HNVFRYnY4UmR1ZWIybjJMNnBHeTFfbXNlNGI5X2s5ZFhvNHlOeWgxLTNVWm5USklKWVRCeE5SclNUekgxYUhsZkVn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-24T07:00:00+00:00", "source_names": ["Stock Titan"], "target_scope": "", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": false, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 1.6e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": null, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": [], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "24 Jul 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "", "provider_directional_mass": null}, {"url": "https://www.fiercebiotech.com/biotech/scribe-records-upsized-129m-ipo-latest-biotech-stock-market-debut", "tier": "direct", "title": "Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds", "topics": ["IPO", "Life Sciences"], "summary": "Scribe Therapeutics has successfully upsized its IPO, raising $128.7 million to advance its gene-editing pipeline focused on lipid-lowering therapies. The company's lead candidate, STX-1150, targets the PCSK9 gene for cardiovascular disease, with topline data expected in the first half of 2027. Scribe plans to use the proceeds to fund clinical trials for STX-1150, STX-1400, and STX-1200, aiming to offer personalized genetic medicine options for patients.", "age_days": 24.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "6e3eb10fb5682414ba75c15b20bbf53dec741935f06ff0c0864c1b2592a22a01", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.fiercebiotech.com/biotech/scribe-records-upsized-129m-ipo-latest-biotech-stock-market-debut", "source_name": "Fierce Biotech", "published_at": "2026-07-24T04:00:00", "source_names": ["Fierce Biotech"], "target_scope": "Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds Scribe Therapeutics has successfully upsized its IPO, raising $128.7 million to advance its gene-editing pipeline focused on lipid-lowering therapies. Scribe plans to use the proceeds to fund clinical trials for STX-1150, STX-1400, and STX-1200, aiming to offer personalized genetic medicine options for patients.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 1.2e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["MRK", "SCTX", "SCTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "24 Jul 2026 04:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX", "provider_directional_mass": 0.4322}, {"url": "https://www.globenewswire.com/news-release/2026/07/24/3332675/0/en/Scribe-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html", "tier": "direct", "title": "Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering", "topics": ["Biotech", "Crispr", "Genetic Medicine", "Initial Public Offering", "Initial Public Offerings", "IPO"], "summary": "ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (\u201cScribe Therapeutics\u201d) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial public offering of 8,580,000 shares of its common stock at the high end of the range at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other of", "age_days": 24.1, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "48e8412c72baacba5de5311b20132075d9209dc5478ba9e6d0588789d079819c", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "press_release", "source_link": "https://www.globenewswire.com/news-release/2026/07/24/3332675/0/en/Scribe-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html", "source_name": "globenewswire.com", "published_at": "2026-07-24T01:08:00+00:00", "source_names": ["globenewswire.com"], "target_scope": "Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (\u201cScribe Therapeutics\u201d) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial public offering of 8,580,000 shares of its common stock at the high end of the range at a public offering price of $15.00 per share.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 1.6e-05, "influence_label": "None", "provider_symbol": "SCTX.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["SCTX.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "24 Jul 2026 01:08", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.US", "provider_directional_mass": 0.126}, {"url": "https://finance.yahoo.com/healthcare/articles/scribe-secures-129m-rare-gene-211800640.html", "tier": "direct", "title": "Scribe secures $129M in a rare gene editing IPO", "topics": ["Biotech", "Gene Editing", "Initial Public Offering", "IPO"], "summary": "This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Scribe Therapeutics has raised close to $129 millionin the first initial public offering for a developer of gene editing medicines in more than two years. The startup on Thursday sold 8.58 million shares at $15 apiece, topping projections set earlier this week. Shares will begin trading Friday on the Nasdaq stock exchange under the ticker symbol \"SCTX.\" Biotech IPOs have been on an upswing in 2026. Including Scribe's offering, 14 companies have price", "age_days": 24.3, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "9d173854fedec4d9fa40afce3ffb973e2efb78932bcd4508901eb1208757b088", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/scribe-secures-129m-rare-gene-211800640.html", "source_name": "finance.yahoo.com", "published_at": "2026-07-23T21:18:00+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Scribe secures $129M in a rare gene editing IPO Scribe Therapeutics has raised close to $129 millionin the first initial public offering for a developer of gene editing medicines in more than two years. Shares will begin trading Friday on the Nasdaq stock exchange under the ticker symbol \"SCTX.\" Biotech IPOs have been on an upswing in 2026. Including Scribe's offering, 14 companies have price", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 1.7e-05, "influence_label": "None", "provider_symbol": "SCTX.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.526, "provider_symbols": ["SCTX.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Jul 2026 21:18", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "SCTX.US", "provider_directional_mass": 0.08}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Early balanced news score", "summary": "25 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 50, "display": "50", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 17, "display": "17", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 100, "display": "100%", "tone": "positive", "note": "25 company stories"}, {"label": "Story agreement", "value": 100, "display": "100", "tone": "positive", "note": "0/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 0, "note": "0.0 after freshness weighting"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Company relevance", "value": 100, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 56, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 100, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 0, "note": "less reliance on one publisher"}], "freshness": 56, "source_independence": 0, "timeline": [{"date": "2026-07-19", "label": "19 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-20", "label": "20 Jul", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-21", "label": "21 Jul", "count": 0, "score": null, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-22", "label": "22 Jul", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-23", "label": "23 Jul", "count": 1, "score": 50, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-07-24", "label": "24 Jul", "count": 4, "score": 50, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 2, "score": 59, "tone": "positive", "x": 263.1, "y": 118.6, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 4, "score": 50, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 3, "score": 50, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 39.0, "volume_y": 227.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 452.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-14", "label": "14 Aug", "count": 0, "score": null, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-15", "label": "15 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-16", "label": "16 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}, {"date": "2026-08-17", "label": "17 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 13.0, "volume_y": 253.0}], "timeline_points": "168.3,135.0 199.9,135.0 263.1,118.6 294.7,135.0 389.4,135.0 515.8,135.0 579.0,135.0 736.9,135.0 768.5,135.0 800.1,135.0 831.7,135.0 894.8,135.0 926.4,135.0 958.0,135.0", "timeline_has_signal": true, "timeline_start": "19 Jul", "timeline_mid": "03 Aug", "timeline_end": "17 Aug", "momentum": {"label": "Stable but thin", "tone": "neutral", "recent_score": 50, "prior_score": 50, "delta": 0, "recent_count": 3, "prior_count": 4, "volume_delta": -1, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "New stories need a baseline", "tone": "neutral", "latest_score": 50, "baseline_score": 50, "delta": null, "latest_count": 1, "baseline_count": 8, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 1, "share": 4}, {"label": "1 to 3 days", "count": 2, "share": 8}, {"label": "4 to 7 days", "count": 6, "share": 24}, {"label": "8 to 14 days", "count": 1, "share": 4}, {"label": "15 to 21 days", "count": 6, "share": 24}, {"label": "22 to 30 days", "count": 9, "share": 36}], "source_profile": [{"label": "Stock Titan", "count": 10, "share": 40, "score": 50, "tone": "neutral"}, {"label": "TradingView", "count": 4, "share": 16, "score": 50, "tone": "neutral"}, {"label": "Zacks Investment Research", "count": 3, "share": 12, "score": 50, "tone": "neutral"}, {"label": "Fierce Biotech", "count": 2, "share": 8, "score": 50, "tone": "neutral"}, {"label": "WSJ", "count": 1, "share": 4, "score": 62, "tone": "positive"}, {"label": "Benzinga", "count": 1, "share": 4, "score": 50, "tone": "neutral"}, {"label": "Market source", "count": 1, "share": 4, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Market update", "count": 17, "share": 68, "score": 50, "tone": "neutral"}, {"label": "Earnings", "count": 5, "share": 20, "score": 50, "tone": "neutral"}, {"label": "Deals and strategy", "count": 3, "share": 12, "score": 50, "tone": "neutral"}], "topics": [{"label": "Life Sciences", "count": 12, "share": 48}, {"label": "IPO", "count": 11, "share": 44}, {"label": "Finance", "count": 8, "share": 32}, {"label": "Initial Public Offering", "count": 2, "share": 8}, {"label": "Financial Markets", "count": 2, "share": 8}, {"label": "Biotech", "count": 2, "share": 8}, {"label": "Initial Public Offerings", "count": 1, "share": 4}, {"label": "Genetic Medicine", "count": 1, "share": 4}, {"label": "Gene Editing", "count": 1, "share": 4}, {"label": "Earnings", "count": 1, "share": 4}], "supporting": [{"label": "Direct evidence", "text": "25 current stories are mapped specifically to SCTX."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}, {"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.000."}, {"label": "Confidence", "text": "Confidence is 17/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE5pR3NWa2dyendscW05RG1SRFhTdnI5V1g5MDg4X19KS25xTTJiUWJiSEFPRks3X0JTc2otVVZrUjlfd1pOeEtlem5WdFdpOFdTbkJjNA?oc=5", "tier": "direct", "title": "Scribe Therapeutics (SCTX) Stock Analysis Report | Financials & Insights", "topics": [], "summary": "", "age_days": 0.2, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE5pR3NWa2dyendscW05RG1SRFhTdnI5V1g5MDg4X19KS25xTTJiUWJiSEFPRks3X0JTc2otVVZrUjlfd1pOeEtlem5WdFdpOFdTbkJjNA?oc=5", "source_name": "Benzinga", "published_at": "2026-08-17T00:44:57+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 94.8, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.06905, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "17 Aug 2026 00:44", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, "article_count": 25, "updated_at": "2026-08-17T04:24:40.163174+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 154.8, "label": "24 Jul 2026", "close": 21.65, "index": 100.0}, {"x": 333.5, "y": 204.2, "label": "31 Jul 2026", "close": 19.48, "index": 90.0}, {"x": 624.9, "y": 55.8, "label": "07 Aug 2026", "close": 26.0, "index": 120.1}, {"x": 916.4, "y": 175.7, "label": "14 Aug 2026", "close": 20.73, "index": 95.8}], "sentiment_points": [{"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 21.65, "label": "24 Jul 2026", "score": 50, "stories": 5, "raw_score": 50, "confidence": 0, "price_change": null, "x": 83.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "neutral", "close": 19.48, "label": "31 Jul 2026", "score": 50, "stories": 14, "raw_score": 62, "confidence": 19, "price_change": -10.0, "x": 375.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "neutral", "close": 26.0, "label": "07 Aug 2026", "score": 50, "stories": 16, "raw_score": 62, "confidence": 16, "price_change": 33.5, "x": 666.5, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 20.73, "label": "14 Aug 2026", "score": 50, "stories": 22, "raw_score": 62, "confidence": 16, "price_change": -20.3, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "price_path": "42.0,154.8 333.5,204.2 624.9,55.8 916.4,175.7", "sentiment_path": "83.6,130.0 375.1,130.0 666.5,130.0 958.0,130.0", "score_version": "evidence-v10", "price_change": -4.2, "sentiment_change": 0, "recent_pairs": [{"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 20.73, "label": "14 Aug 2026", "score": 50, "stories": 22, "raw_score": 62, "confidence": 16, "price_change": -20.3, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "neutral", "close": 26.0, "label": "07 Aug 2026", "score": 50, "stories": 16, "raw_score": 62, "confidence": 16, "price_change": 33.5, "x": 666.5, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "neutral", "close": 19.48, "label": "31 Jul 2026", "score": 50, "stories": 14, "raw_score": 62, "confidence": 19, "price_change": -10.0, "x": 375.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 21.65, "label": "24 Jul 2026", "score": 50, "stories": 5, "raw_score": 50, "confidence": 0, "price_change": null, "x": 83.6, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 20.73, "start_label": "24 Jul", "mid_label": "07 Aug", "end_label": "14 Aug", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"tone": "neutral", "delta": 0, "label": "24 Jul 23:59", "score": 50, "height": 4, "articles": 5, "confidence": 0, "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start"}, {"tone": "neutral", "delta": 2, "label": "26 Jul 23:59", "score": 52, "height": 4, "articles": 7, "confidence": 34, "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 34, "score_change_display": "+2"}, {"tone": "neutral", "delta": 1, "label": "27 Jul 23:59", "score": 51, "height": 4, "articles": 11, "confidence": 29, "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1"}, {"tone": "neutral", "delta": 1, "label": "30 Jul 23:59", "score": 51, "height": 4, "articles": 14, "confidence": 21, "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -8, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "03 Aug 23:59", "score": 50, "height": 4, "articles": 15, "confidence": 17, "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "-1"}, {"tone": "neutral", "delta": 0, "label": "05 Aug 23:59", "score": 50, "height": 4, "articles": 16, "confidence": 17, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "10 Aug 23:59", "score": 50, "height": 4, "articles": 18, "confidence": 16, "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "11 Aug 23:59", "score": 50, "height": 4, "articles": 20, "confidence": 16, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "12 Aug 23:59", "score": 50, "height": 4, "articles": 21, "confidence": 16, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "13 Aug 23:59", "score": 50, "height": 4, "articles": 22, "confidence": 16, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "15 Aug 23:59", "score": 50, "height": 4, "articles": 23, "confidence": 16, "short_label": "15 Aug", "collected_at": "2026-08-15T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "16 Aug 23:59", "score": 50, "height": 4, "articles": 24, "confidence": 16, "short_label": "16 Aug", "collected_at": "2026-08-16T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "17 Aug 04:24", "score": 50, "height": 4, "articles": 25, "confidence": 16, "short_label": "17 Aug", "collected_at": "2026-08-17T04:24:40.040540+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 13, "span_label": "23 days", "first_score": 50, "latest_score": 50, "net_change": 0, "net_change_display": "+0", "direction": "Broadly stable", "high_score": 52, "low_score": 50, "latest_confidence": 16, "confidence_change": 16, "latest_articles": 25, "article_change": 20, "latest_label": "17 Aug 04:24", "latest_evidence_label": "Provisional", "chart_rows": [{"tone": "neutral", "delta": 0, "label": "24 Jul 23:59", "score": 50, "height": 4, "articles": 5, "confidence": 0, "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v10", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start", "x": 42.0, "y": 135.0}, {"tone": "neutral", "delta": 2, "label": "26 Jul 23:59", "score": 52, "height": 4, "articles": 7, "confidence": 34, "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 34, "score_change_display": "+2", "x": 118.3, "y": 131.4}, {"tone": "neutral", "delta": 1, "label": "27 Jul 23:59", "score": 51, "height": 4, "articles": 11, "confidence": 29, "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1", "x": 194.7, "y": 133.2}, {"tone": "neutral", "delta": 1, "label": "30 Jul 23:59", "score": 51, "height": 4, "articles": 14, "confidence": 21, "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -8, "score_change_display": "+0", "x": 271.0, "y": 133.2}, {"tone": "neutral", "delta": 0, "label": "03 Aug 23:59", "score": 50, "height": 4, "articles": 15, "confidence": 17, "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "-1", "x": 347.3, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "05 Aug 23:59", "score": 50, "height": 4, "articles": 16, "confidence": 17, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0", "x": 423.7, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "10 Aug 23:59", "score": 50, "height": 4, "articles": 18, "confidence": 16, "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 500.0, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "11 Aug 23:59", "score": 50, "height": 4, "articles": 20, "confidence": 16, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0", "x": 576.3, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "12 Aug 23:59", "score": 50, "height": 4, "articles": 21, "confidence": 16, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0", "x": 652.7, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "13 Aug 23:59", "score": 50, "height": 4, "articles": 22, "confidence": 16, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0", "x": 729.0, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "15 Aug 23:59", "score": 50, "height": 4, "articles": 23, "confidence": 16, "short_label": "15 Aug", "collected_at": "2026-08-15T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0", "x": 805.3, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "16 Aug 23:59", "score": 50, "height": 4, "articles": 24, "confidence": 16, "short_label": "16 Aug", "collected_at": "2026-08-16T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0", "x": 881.7, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "17 Aug 04:24", "score": 50, "height": 4, "articles": 25, "confidence": 16, "short_label": "17 Aug", "collected_at": "2026-08-17T04:24:40.040540+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0", "x": 958.0, "y": 135.0}], "chart_points": "42.0,135.0 118.3,131.4 194.7,133.2 271.0,133.2 347.3,135.0 423.7,135.0 500.0,135.0 576.3,135.0 652.7,135.0 729.0,135.0 805.3,135.0 881.7,135.0 958.0,135.0", "changes": [{"tone": "neutral", "delta": 0, "label": "17 Aug 04:24", "score": 50, "height": 4, "articles": 25, "confidence": 16, "short_label": "17 Aug", "collected_at": "2026-08-17T04:24:40.040540+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "16 Aug 23:59", "score": 50, "height": 4, "articles": 24, "confidence": 16, "short_label": "16 Aug", "collected_at": "2026-08-16T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "15 Aug 23:59", "score": 50, "height": 4, "articles": 23, "confidence": 16, "short_label": "15 Aug", "collected_at": "2026-08-15T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "13 Aug 23:59", "score": 50, "height": 4, "articles": 22, "confidence": 16, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "12 Aug 23:59", "score": 50, "height": 4, "articles": 21, "confidence": 16, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "11 Aug 23:59", "score": 50, "height": 4, "articles": 20, "confidence": 16, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "10 Aug 23:59", "score": 50, "height": 4, "articles": 18, "confidence": 16, "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "05 Aug 23:59", "score": 50, "height": 4, "articles": 16, "confidence": 17, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v10", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "+0"}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}